BETHLEHEM, Pa., Oct. 19 /PRNewswire/ -- Particle Sciences Inc. (PSI), a leading pharmaceutical CRO and SoluBest have entered into a licensing and technology development agreement. Under the agreement, Particle Sciences will be the exclusive contract research provider in the U.S. for SoluBest's Solumer technology. Particle Sciences will offer Solumer formulation and clinical trial supply manufacturing to Pharmaceutical and Biotech companies. The patented Solumer approach utilizes GRAS polymers to create drug/polymer complexes that result in greatly improved drug solubility and bioavailability. Once formulations come in contact with aqueous media, they spontaneously form colloidal dispersions, resulting in increased bioavailability of the active pharmaceutical ingredient. The process is easily adaptable to a wide range of molecules, making it attractive for both new chemical entities and life-cycle management challenges.
According Amir Zalcenstein, SoluBest's CEO, "We are thrilled to partner with Particle Sciences. They are at the cutting edge of drug delivery technologies and provide us with greater access to the U.S. marketplace. Additionally, by leveraging their significant GMP/GLP infrastructure, we are able to offer potential licensees a clear development path with a world-class CRO. Moreover, following our recent licensing deal with Dr. Reddy's, we're seeing a lot of interest in our technology, and partnering with Particle Sciences is essential in order to meet the increased demand."
Mark Mitchnick, CEO of Particle Sciences adds, "The Solumer technology fits perfectly with our growth strategy of adopting truly value added drug delivery approaches to our portfolio. This is a proven technology that is both cost effective and scalable. It will find application with both NCE's and generics. Under this agreement, Particle Sciences will use Solumer technology to develop drug products for our clients. We are very excited to be working with SoluBest and are already evaluating the technology for specific projects."
SoluBest is a clinical-stage developer of enabling drug delivery technologies, established in 2001 with the intention of developing smart polymer, self-assembling nano-particle constructs. The company is located at the Weizmann Science Park in Ness Ziona, Israel, and employs a team of experienced polymer and analytical chemists.
Particle Sciences is an integrated provider of drug development services. Particle Sciences focuses on emulsions, gels, particulates and drug/device combination products with a focus on API's with difficult solubility profiles. Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic. The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania. Visit www.particlesciences.com, email email@example.com or contact us at (610) 861- 4701 for information.
SOURCE Particle Sciences Inc.